Last reviewed · How we verify

Advair HFA MDI 115/21

Allergy and Asthma Center of El Paso · FDA-approved active Small molecule

Advair HFA combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.

Advair HFA combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameAdvair HFA MDI 115/21
Also known asAdvair = fluticasone proprionate plus salmeterol
SponsorAllergy and Asthma Center of El Paso
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination
TargetGlucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway inflammation. Salmeterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: